| Subject: | FDA Approves New Medication for Pain Management |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Wed, 13 Oct 2004 - 10:00 am |
| The FDA has approved the drug Palladone (hydromorphone hydrochloride) capsules for the treatment of moderate to severe pain. Palladone is an opioid based medication, delivered in an extended-release formulation. Palladone (which is stronger than Oxycontin) is intended for use in patients who are currently receiving opioid therapy and require continuous around-the-clock opioid pain relief for an extended period of time due to severed, persistent pain. The FDA notes that Palladone should only be... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
External Links:
Related MCN Products:
|
|
StayAlert! provides immediate notification of regulatory body legislation impacting the healthcare industry, helping you to meet regulatory compliance. Subscribers are notified of any new or revised regulations, provided with a summary of the regulation, followed by an implementation action plan and/or policy. Designed as an e-mail "push" method for rapid customer notification of healthcare compliance issues, paired with interpretative analysis and practical application, the StayAlert!® Virtual Compliance Administrator™ saves you time and money. The strength of StayAlert! rests in its ability to allow healthcare organizations to streamline their businesses using the Internet as a foundation architecture. StayAlert! provides cost containment and reduction through elimination of unnecessary overhead, and work caused by errors or poor access to information. |
|
